Earnings summaries and quarterly performance for Bioventus.
Executive leadership at Bioventus.
Board of directors at Bioventus.
GJ
Guido J. Neels
Detailed
Director
GP
Guy P. Nohra
Detailed
Director
JA
John A. Bartholdson
Detailed
Director
MP
Martin P. Sutter
Detailed
Director
MK
Mary Kay Ladone
Detailed
Director
MM
Michelle McMurry-Heath
Detailed
Director
PJ
Patrick J. Beyer
Detailed
Director
PG
Philip G. Cowdy
Detailed
Director
SM
Susan M. Stalnecker
Detailed
Director
WA
William A. Hawkins
Detailed
Chairperson
Research analysts who have asked questions during Bioventus earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
4 questions for BVS
Also covers: ATEC, AXGN, ENOV +10 more
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for BVS
Also covers: AVDL, BFLY, CELC +17 more
RM
Robert Marcus
JPMorgan Chase & Co.
3 questions for BVS
Also covers: ABT, BAX, BDX +21 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
1 question for BVS
Also covers: ATRC, CBLL, IART +4 more
MP
Matthew Park
Cantor Fitzgerald
1 question for BVS
Also covers: AXGN, CERS, ORGO +5 more
Recent press releases and 8-K filings for BVS.
BioStem Technologies Launches New American Amnion Product Line
BVS
Product Launch
New Projects/Investments
- BioStem Technologies, Inc. (OTC: BSEM) launched its new American Amnion product line at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference on December 10-13, 2025.
- The new line, comprising American Amnion and American Amnion AC, consists of placental-derived allografts for advanced wound care, produced using the company's proprietary BioRetain® technology.
- Clinical studies have demonstrated the products' efficacy, with one study showing a 53% wound closure probability versus 31% for standard of care, and another demonstrating a 14% reduction in time to closure and 27% fewer applications compared to a competitor.
- The launch aims to address the needs of the underserved veteran population with chronic wounds, aligning with a 50% increase in placental-based product use within the VA system over the past five years.
Dec 10, 2025, 12:00 PM
Bioventus CEO highlights growth strategy and financial improvements
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Bioventus (BVS) aims to become a $1 billion high-growth, high-profit, high-cash flow company, currently generating over $550 million in annual revenue across Pain Treatments, Surgical Solutions, and Restorative Therapies.
- The company anticipates growing nearly 2X the weighted average market growth rate this year, supported by a peer-leading gross margin in the mid-70s and an EBITDA margin guidance of just over 20%.
- Significant financial improvements are expected, with cash flow projected to nearly double this year and net leverage anticipated to drop below 2.5x by year-end.
- Growth is driven by core, expansion, and emerging categories, with emerging growth drivers like PNS and PRP expected to contribute at least 200 basis points of growth next year, following the recent FDA 510(k) clearance for StimTrial.
Dec 3, 2025, 3:10 PM
Bioventus Presents Investment Opportunity and Financial Performance at 2025 Piper Sandler Healthcare Conference
BVS
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Bioventus highlighted a $6.4 billion market opportunity and reported $564 million in LTM Global Proforma Revenue as of September 27, 2025.
- The company projects significant financial improvement for 2025, with 7.0% organic growth and an Adjusted EBITDA Margin of 20.2%, based on the midpoint of guidance provided on March 11, 2025.
- Bioventus aims to accelerate cash flow and reduce leverage, with Cash from Operations projected to reach $66.1 million in 2025 and the Net Leverage Ratio expected to be below 2.5x by the end of 2025.
- The company maintains a peer-leading, consistent mid-70s gross margin, which supports re-investment in growth opportunities and EBITDA margin expansion.
Dec 3, 2025, 3:10 PM
Bioventus CEO Highlights Strong Growth Trajectory and Financial Improvements
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Bioventus, led by CEO Rob Claypoole, generates over $550 million in annual revenue and operates in a $6 billion market opportunity across pain treatment, surgical solutions, and restorative therapies.
- The company has demonstrated above-market growth for the past eight quarters and expects to grow nearly 2X the weighted average market growth rate this year, aiming to become a $1 billion high-growth, high-profit, high-cash flow company.
- Bioventus projects significant financial improvements, including a peer-leading gross margin in the mid-70s, an EBITDA margin guidance of just over 20% for this year (a 100 basis points improvement), and cash flow expected to nearly double this year.
- The company is focused on three growth driver categories: Core (HA, BGS, fracture care), Expansion (Ultrasonics, International), and Emerging (PNS, PRP), with emerging drivers like PNS and PRP expected to generate at least 200 basis points of growth next year.
- Leverage is expected to drop below 2.5x by the end of this year, providing greater optionality for capital deployment.
Dec 3, 2025, 3:10 PM
Bioventus Announces Q3 2025 Results and Reaffirms Full-Year Guidance
BVS
Earnings
Guidance Update
Product Launch
- Bioventus reported Q3 2025 revenue of $139 million, comparable to the prior year due to a divestiture, with 8% organic growth.
- The company achieved a GAAP net income of $3 million in Q3 2025, an improvement from a net loss of $5 million in the prior year, and Adjusted EBITDA increased by 13% to $27 million.
- Bioventus reaffirmed its full-year 2025 financial guidance, expecting net sales between $560 million and $570 million and Adjusted EBITDA between $112 million and $116 million.
- Pilot launches for Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP) are progressing well and are anticipated to provide at least 200 basis points of profitable growth in 2026.
Nov 4, 2025, 1:30 PM
Bioventus Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance
BVS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bioventus reported Q3 2025 revenue of $139 million, achieving 8% organic growth, and adjusted EBITDA increased by 13% to $27 million, expanding the adjusted EBITDA margin by 220 basis points.
- Adjusted earnings per diluted share for Q3 2025 increased by 200% to $0.15.
- The company generated $30 million in cash flow from operations in Q3 2025, an increase of $20 million compared to the prior year, and reduced debt by $19 million, bringing the net leverage ratio below three times.
- Bioventus reaffirmed its 2025 financial guidance, including organic revenue growth of 6%-8%, adjusted EBITDA of $112 million-$116 million, and EPS of $0.64-$0.68.
- Strategic initiatives like the limited launch of StimTrial and Talisman (PNS) are tracking ahead of expectations, and the new PRP system, Excel, is receiving positive feedback, with both expected to contribute at least 200 basis points of profitable growth in 2026.
Nov 4, 2025, 1:30 PM
Bioventus Inc. Reports Strong Q3 2025 Financial Results and Reaffirms Full-Year Guidance
BVS
Earnings
Guidance Update
Debt Issuance
- Bioventus Inc. reported Q3 2025 revenue of $138.7 million, with organic revenue advancing 8%, and saw significant increases in profitability with GAAP earnings of $0.05 per diluted share and Non-GAAP earnings of $0.15 per diluted share.
- Cash from operations surged 192% to $30.1 million for Q3 2025.
- The company reaffirmed its full-year 2025 financial guidance, projecting net sales between $560 million and $570 million, Adjusted EBITDA of $112 million to $116 million, and Non-GAAP EPS of $0.64 to $0.68.
- Key strategic advancements include the launch of the XCELL PRP System and StimTrial/TalisMann, and securing a new Credit Agreement providing a $300 million term loan and $100 million revolving credit facility to enhance liquidity and extend debt maturity.
Nov 4, 2025, 12:37 PM
Bioventus Reports Third Quarter 2025 Financial Results
BVS
Earnings
Guidance Update
Product Launch
- Bioventus reported Q3 2025 revenue of $138.7 million, with 8% organic growth, and GAAP earnings of $0.05 per diluted share, an increase from a loss in the prior-year period.
- Non-GAAP earnings per diluted share rose 200% to $0.15, and cash from operations increased 192% to $30.1 million for the quarter ended September 27, 2025.
- The company reaffirmed its full-year 2025 guidance, projecting net sales of $560 million to $570 million, Adjusted EBITDA of $112 million to $116 million, and Non-GAAP EPS of $0.64 to $0.68.
- Key business developments include the launch of the XCELL PRP System and StimTrial and TalisMann PNS products, and a new $300 million term loan and $100 million revolving credit facility secured on July 31, 2025, expected to save over $2 million in annual interest expense.
Nov 4, 2025, 12:30 PM
BioStem Technologies Reports Positive Clinical Trial Results for BioRetain® in Diabetic Foot Ulcers
BVS
Product Launch
New Projects/Investments
- BioStem Technologies, Inc. (OTC: BSEM) announced positive top-line results from its clinical trial for BioRetain® - Processed Amnion Chorion (BR-AC), evaluating its effectiveness for non-healing diabetic foot ulcers (DFUs).
- The trial demonstrated that the probability of healing in the BR-AC arm was 53%, which was significantly higher than the 31% in the standard of care arm, indicating BR-AC was almost twice as likely to achieve lasting wound closure.
- The BR-AC-DFU-101 study, initiated in Q4 2024, was a rigorous multicenter, randomized, controlled trial that enrolled 71 patients with "hard-to-heal wounds".
- CEO Jason Matuszewski stated that these results are expected to drive expanded physician adoption and commercial traction for the BioRetain allograft platform.
Oct 31, 2025, 11:00 AM
Bioventus Outlines Turnaround Success and Future Growth Strategy
BVS
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Bioventus, a $550 million medical device company, has successfully undergone a turnaround, expecting to double cash flow in 2025 from high $30 million to the $60 million to $70 million range.
- The company anticipates achieving 2.5x net leverage or below by the end of 2025, a significant reduction from nearly 6x.
- For the current year (2025), Bioventus's guidance midpoint projects 7% growth and $114 million in EBITDA.
- Key growth drivers include the ultrasonics portfolio (acquired in 2022), which has shown double-digit growth and has long-term expansion potential beyond spine into neuro and general surgery.
- New product launches, Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP), are expected to significantly contribute to growth starting in 2026, potentially adding 200 basis points of growth combined.
Sep 10, 2025, 5:05 PM
Quarterly earnings call transcripts for Bioventus.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more